BioScrip Inc (NASDAQ:BIOS) – Research analysts at Barrington Research lifted their FY2018 EPS estimates for shares of BioScrip in a report issued on Monday, Zacks Investment Research reports. Barrington Research analyst M. Petusky now forecasts that the company will earn ($0.22) per share for the year, up from their prior estimate of ($0.23).
A number of other research firms have also recently issued reports on BIOS. ValuEngine upgraded BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. SunTrust Banks set a $4.00 price objective on BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $3.63.
BioScrip (NASDAQ:BIOS) traded down $0.10 on Wednesday, hitting $2.90. The stock had a trading volume of 2,094,300 shares, compared to its average volume of 1,134,750. The company has a market capitalization of $369.80, a PE ratio of -4.68 and a beta of 0.27. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11. BioScrip has a 1-year low of $1.21 and a 1-year high of $3.39.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $198.70 million during the quarter, compared to analyst estimates of $202.91 million. The company’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.12) EPS.
A number of institutional investors have recently bought and sold shares of BIOS. Alta Fundamental Advisers LLC boosted its stake in BioScrip by 36.9% in the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after purchasing an additional 818,000 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in BioScrip in the third quarter worth $1,642,000. Gilder Gagnon Howe & Co. LLC boosted its stake in BioScrip by 3.6% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock worth $43,352,000 after purchasing an additional 553,201 shares in the last quarter. FMR LLC boosted its stake in BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after purchasing an additional 520,231 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in BioScrip in the third quarter worth $857,000. 84.63% of the stock is currently owned by institutional investors.
In related news, CEO Daniel E. Greenleaf purchased 15,000 shares of the stock in a transaction on Thursday, November 9th. The shares were purchased at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the completion of the transaction, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at approximately $62,930. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://ledgergazette.com/2018/01/17/bioscrip-inc-to-post-fy2018-earnings-of-0-22-per-share-barrington-research-forecasts-bios.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.